It isn't to me. Either I spectacularly misunderstand the treatment capabilities of PAT-SM6 as a standalone drug (not combined) or others do.
I wouldn't say it is a case of 1 + 1 = 2 but rather 0.6 + 0.1 = 1 where PAT-SM6 would be the 0.1. Onyx may want PAT-SM6 but we need a Kyprolis.
ONXY trial, page-25
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(12.5%) |
Mkt cap ! $7.201M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $564 | 161.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 39 | 29348732 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 26555626 | 17 |
View Market Depth
| Last trade - 12.59pm 18/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |